Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low - Time to Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $34.60 and last traded at $34.74, with a volume of 232121 shares changing hands. The stock had previously closed at $36.24.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AMPH. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price for the company. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of "Hold" and an average target price of $60.33.

Amphastar Pharmaceuticals Trading Up 0.1 %

The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The business's 50 day moving average price is $41.15 and its 200-day moving average price is $44.04. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 1.12 and a beta of 0.82.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO William J. Peters sold 7,426 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,533 shares of company stock valued at $1,987,482 in the last quarter. Insiders own 27.10% of the company's stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of large investors have recently modified their holdings of AMPH. GAMMA Investing LLC boosted its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after purchasing an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after buying an additional 398 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $78,000. Mirae Asset Global Investments Co. Ltd. increased its position in Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after acquiring an additional 301 shares during the period. Finally, nVerses Capital LLC raised its stake in shares of Amphastar Pharmaceuticals by 18.2% during the third quarter. nVerses Capital LLC now owns 2,600 shares of the company's stock valued at $126,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.